Radiotherapy device manufacturer Resonant Medical said that its Restitu 3D ultrasound image-guided radiation therapy platform has received 510(k) marketing clearance from the Food and Drug Administration.
The Restitu system acquires 3D ultrasound patient data and compares it to 3D ultrasound data acquired in a CT-simulator room to quantify changes in organ position and morphology. The Montreal-based firm said that it will be making the product immediately available to U.S. cancer centers.
By AuntMinnie.com staff writers
December 21, 2004
Related Reading
New financing for Resonant, October 7, 2004
Copyright © 2004 AuntMinnie.com